(Q36620540)

15 August 2017

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF (English)

1 reference

15 August 2017

1 reference

1 reference

5

Blomqvist C

1 reference

15 August 2017

Poikonen P

1

1 reference

15 August 2017

Saarto T

series ordinal

2

1 reference

15 August 2017

Lundin J

series ordinal

3

1 reference

15 August 2017

Joensuu H

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

80

1 reference

15 August 2017

11

1 reference

15 August 2017

1763-1766

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690594

15 August 2017

0 references

cites work

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

Dose-response effect of adjuvant chemotherapy in breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

Combination chemotherapy for breast cancer metastatic to bone marrow

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

The calculation of actual or received dose intensity: a comparison of published methods.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363113

Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study

20 September 2018

1 reference

12 December 2020

Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial

1 reference

12 December 2020

A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer

1 reference

12 December 2020

Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results

1 reference

12 December 2020

Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer

1 reference

12 December 2020

Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group

1 reference

12 December 2020

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

12 December 2020

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

12 December 2020

Nonparametric Estimation from Incomplete Observations

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690594

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6690594

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

10468293

1 reference